You are currently viewing a new version of our website. To view the old version click .

Current Oncology, Volume 29, Issue 10

October 2022 - 104 articles

Cover Story: The combination of an immune checkpoint inhibitor and a multitarget tyrosine kinase inhibitor has become a standard first-line treatment for metastatic renal cell cancer, changing the therapeutic landscape. Along with survival improvement, combination therapy has raised complexity in adverse event handling. Toxicities could be insidious in clinical presentation, and proper attribution to either of the two classes of drugs could be challenging. Key points that clinicians can rely on to achieve an optimal adverse events management are the adherence to immune-related toxicities’ international guidelines, the application of proper expert-defined algorithms, the knowledge sharing within a multidisciplinary dedicated board, and accurate patient information. View this paper
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (104)

  • Article
  • Open Access
4 Citations
2,874 Views
8 Pages

The Impact of Chemosensitivity on the Outcome of Brain Metastases in Small-Cell Lung Cancer: A Retrospective Analysis

  • Jintao Ma,
  • Chunliu Meng,
  • Jia Tian,
  • Kai Ren,
  • Huijun Jia,
  • Meng Yan,
  • Liming Xu and
  • Lujun Zhao

21 October 2022

Purpose: The purpose of this study was to investigate the prognostic differences between patients with small-cell lung cancer (SCLC) with different chemosensitivity to first-line chemotherapy who developed brain metastasis (BM) as the first site of p...

  • Article
  • Open Access
5 Citations
3,318 Views
15 Pages

21 October 2022

Few studies have focused on the link between active surveillance (AS) and Gleason score upgrade (GSU) and its impact on the prognosis of patients with prostate cancer (PCa). This study aimed to analyze the effect of AS duration on GSU and prognostic...

  • Article
  • Open Access
23 Citations
3,970 Views
11 Pages

Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients

  • Justin Tong,
  • Adi Kartolo,
  • Cynthia Yeung,
  • Wilma Hopman and
  • Tara Baetz

20 October 2022

ICI therapy has greatly improved patient outcomes in melanoma, but at the cost of immune-related adverse events (irAEs). Data on the chronicity of irAEs, especially in real-world settings, are currently limited. We performed a retrospective chart rev...

  • Article
  • Open Access
5 Citations
4,338 Views
10 Pages

Sleep Disturbance Affects Immune Factors in Clinical Liver Cancer Patients

  • Zuoyun Wang,
  • Yan Wang,
  • Jing Huang,
  • Jietian Xu,
  • Fangzhen Chen,
  • Zidan Zhu,
  • Lingling Gao,
  • Jie Qin,
  • Binbin Liu and
  • Chunmin Liang

20 October 2022

Background: Sleep–wake disturbance is prevalent in patients with liver cancer, but there is no direct evidence of its association and related biological mechanisms. Our study was to assess quality of sleep and to describe prevalence of sleep di...

  • Review
  • Open Access
11 Citations
3,310 Views
11 Pages

Improving the Integration between Palliative Radiotherapy and Supportive Care: A Narrative Review

  • Erica Scirocco,
  • Francesco Cellini,
  • Costanza Maria Donati,
  • Jenny Capuccini,
  • Romina Rossi,
  • Milly Buwenge,
  • Luigi Montanari,
  • Marco Maltoni and
  • Alessio Giuseppe Morganti

19 October 2022

Palliative radiotherapy (PRT) is known to be effective in relieving cancer related symptoms. However, many studies and clinical practice show several barriers hindering its use and worsening the quality of patient support during PRT. Various solution...

  • Perspective
  • Open Access
5 Citations
4,026 Views
7 Pages

Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress

  • Gennaro Gadaleta-Caldarola,
  • Alessandro Rizzo,
  • Vincenzo Dadduzio,
  • Lucia Lombardi,
  • Arianna Gadaleta-Caldarola,
  • Stefania Infusino,
  • Antonio Cusmai,
  • Claudia Citrigno and
  • Gennaro Palmiotti

19 October 2022

Cholangiocarcinoma (CCA) is the second most frequent primary liver cancer, following hepatocellular carcinoma (HCC). Progress in the molecular understanding of CCA has led to the development of several agents, including FGFR inhibitors, such as pemig...

  • Article
  • Open Access
5 Citations
2,831 Views
13 Pages

The Effects of Radiotherapy on Pancreatic Ductal Adenocarcinoma in Patients with Liver Metastases

  • Linxia Wu,
  • Yuting Lu,
  • Lei Chen,
  • Xiaofei Yue,
  • Chunyuan Cen,
  • Chuansheng Zheng and
  • Ping Han

18 October 2022

Background: While radiotherapy has been studied in the treatment of locally advanced pancreatic ductal adenocarcinoma (PDAC), few studies have analyzed the effects of radiotherapy on PDAC in patients with liver metastases. This study aimed to determi...

  • Article
  • Open Access
8 Citations
3,645 Views
12 Pages

Improving Time-to-Treatment for Advanced Non-Small Cell Lung Cancer Patients through Faster Single Gene EGFR Testing Using the Idylla™ EGFR Testing Platform

  • Norbert Banyi,
  • Deepu Alex,
  • Curtis Hughesman,
  • Kelly McNeil,
  • Diana N. Ionescu,
  • Carmen Ma,
  • Stephen Yip and
  • Barbara Melosky

18 October 2022

Introduction: Patients with advanced-stage non-small cell lung cancer (NSCLC) may benefit from a short time-to-treatment (TTT). Predictive biomarker testing is performed prior to treatment, as recommended by various international expert consensus bod...

  • Systematic Review
  • Open Access
6 Citations
3,508 Views
13 Pages

[18F]FDG PET/CT and PET/MR in Patients with Adrenal Lymphoma: A Systematic Review of Literature and a Collection of Cases

  • Laura Evangelista,
  • Filippo Crimì,
  • Andrea Visentin,
  • Giacomo Voltan,
  • Livio Trentin,
  • Carmelo Lacognata,
  • Diego Cecchin and
  • Filippo Ceccato

18 October 2022

Aim. The present study aimed to assess the existing data about Primary Adrenal Lymphoma (PAL) evaluated with FDG PET and to describe a small monocentric series of cases. A systematic analysis (from 2010 to 2022) was made by using PubMed and Web of Sc...

  • Review
  • Open Access
45 Citations
9,967 Views
19 Pages

18 October 2022

Boron neutron capture therapy (BNCT) is a binary modality that is used to treat a variety of malignancies, using neutrons to irradiate boron-10 (10B) nuclei that have entered tumor cells to produce highly linear energy transfer (LET) alpha particles...

of 11

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Curr. Oncol. - ISSN 1718-7729